Welcome to our dedicated page for Celularity SEC filings (Ticker: CELUW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for Celularity Inc. related to its publicly traded warrants under the symbol CELUW, alongside disclosures for its Class A common stock (CELU). Celularity is a regenerative and aging-related cellular medicine company that develops placenta-derived biomaterial products and cell therapies, and its regulatory filings provide detailed information on how these activities intersect with its capital structure, including warrants, debt, and equity financings.
Investors researching CELUW can review current reports on Form 8-K describing material definitive agreements, such as securities purchase agreements for private placements of common stock and warrants, promissory notes secured by company assets, and warrant repricing or adjustment arrangements. Filings also outline the terms of listed warrants, including that each CELUW warrant is exercisable for a fraction of a share of Class A common stock at a stated exercise price, subject to the specific conditions in the warrant agreements attached as exhibits.
Celularity’s filings further describe significant balance sheet and intellectual property transactions, including an Asset Purchase Agreement with Celeniv Pte. Ltd. and a related License Agreement that retired senior secured debt while granting Celularity an exclusive, royalty-bearing license and an option to repurchase the sold intellectual property. Other filings discuss Nasdaq Listing Rule 5250(c)(1) compliance, including notices regarding delayed Form 10-Q reports and subsequent confirmation of compliance after the company filed its quarterly reports.
On Stock Titan, SEC documents such as 10-Qs, 10-Ks, and 8-Ks are updated from EDGAR and can be paired with AI-powered summaries that explain key terms, highlight warrant and equity mechanics, and surface notable changes in obligations or ownership structures. Users can also examine warrant-related exhibits and other equity-linked agreements to understand how CELUW interacts with CELU common stock and how new financings or restructurings may affect existing securities.
Genting-affiliated entities and chairman Lim Kok Thay have increased and reorganised their economic stake in Celularity (CUSIP 151190204) via Amendment No. 6 to their Schedule 13D. Dragasac now holds 6.34 m Class A shares (23.8%). Resorts World Inc. Pte. Ltd. (RWI) holds no shares today but can acquire 4.10 m shares (13.3%) through warrants. Genting Berhad, which controls Dragasac and 50 % of RWI, may be deemed to own 10.44 m shares (33.9%). Including existing shares and newly issued warrants, Mr. Lim could control up to 14.14 m shares, equal to 41 % of the post-exercise base of 34.45 m shares.
Key transaction terms: (i) Extension of three secured loans (combined face value US$27 m minus OID) to 15 Feb 2026 under a 12 Feb 2025 binding term sheet; (ii) repricing of RWI’s existing 1.95 m warrants to US$2.844 (10 % discount to 24 Jul 2025 close) and issuance of a new 500 k warrant on identical terms; (iii) issuance of a US$6.812 m promissory note to Mr. Lim at 2 % interest, maturing 21 Mar 2026, coupled with a 3.70 m warrant at US$2.528 (20 % discount) exercisable for five years after CFIUS clearance (if required); (iv) a portion of Lim Note proceeds will retire the loan from C.V. Starr. No other material contracts were disclosed. The filing confirms no criminal or civil findings against the reporting persons in the past five years.